Posted on: April 5, 2021 Posted by: Administrator_India Comments: 0
Emergent gets $23 million additional order for vaccine production

By Administrator_ India

Capital Sands

Emergent BioSolutions Inc said late on Sunday that a key U.S. agency has increased an order, related to the manufacturing of the Johnson & Johnson COVID-19 vaccine, by $23 million.

The amount will be used to purchase biologics equipment specific to J&J’s vaccine and support the potential manufacturing expansion at the company’s Baltimore Bayview facility, the company said in a statement.

Emergent also said that it will agree to a mutual ramp down of manufacturing of AstraZeneca ( Plc’s COVID-19 vaccine bulk drug substance.

Leave a Comment